Clinical trial · Observational
Transfemoral Versus Transradial Approach in Transarterial Chemoembolization of Hepatocellular Carcinoma
NCT06543030CI-TRIAL-00079551unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Transfemoral Versus Transradial Approach in Transarterial Chemoembolization of Hepatocellular Carcinoma
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- Transfemoral approach (TFA) group
- label
- Transradial approach (TRA) group
Primary outcomes (1)
- measure
- To compare transfemoral approach (TFA) and transradial approach (TRA) in patients undergoing hepatic chemoembolization
- timeFrame
- Baseline
- description
- To compare transfemoral approach (TFA) and transradial approach (TRA) in patients undergoing hepatic chemoembolization in terms of safety, feasibility, and procedural variables, including fluoroscopy time and patient preference.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Patients with Hepatocellular carcinoma of BCLC (Barcelona Clinic Liver Cancer) stage B * Also for BCLC stage A patients, in whom ablative therapy has technical limitations. * Downsizing tumor for resection or transplantation. Exclusion Criteria: * Factors related to liver cirrhosis: * Decompensated cirrhosis (Child-Pugh B and C, score \>8), including jaundice, clinical hepatic encephalopathy, and refractory ascites and/ or hepatorenal syndrome * Impaired portal-vein blood flow (portal-vein thrombus, hepatofugal blood flow) * Factors related to HCC: * Extensive tumor involving the entirety of both lobes of the liver * Malignant portal vein thrombosis * Extra-hepatic metastases * Impaired renal function: * Creatinine ≥2 mg/dl or creatinine clearance \<30 ml/min * Factors related to procedure (Radial artery access): * Existing AV (arteriovenous) fistula or graft * Pervious major surgery to forearm or wrist * Vasculitis * Pervious access failure * Skin infection or compromised integrity * Artery size \<2mm * Intolerance of hyperextended wrist positioning * Severe vasospasm * Vessel tortuosity * Radial loops * Absent or occluded radial artery * Atherosclerotic or calcific PAD (peripheral artery disease) * Coagulopathy INR\>1.5 platelets count \<50.000/mmc
References
Publications (0)
Data not yet available
No reference posted for this study.